Results 241 to 250 of about 1,429,081 (399)

ABSTRACT OF Lectures ON ELECTRO-THERAPEUTICS. [PDF]

, 1875

openalex   +1 more source

Therapeutics

International Journal of Clinical Practice, 1957
openaire   +3 more sources

Stochastic variation in the FOXM1 transcription program mediates replication stress tolerance

Molecular Oncology, EarlyView.
Cellular heterogeneity is a major cause of drug resistance in cancer. Segeren et al. used single‐cell transcriptomics to investigate gene expression events that correlate with sensitivity to the DNA‐damaging drugs gemcitabine and prexasertib. They show that dampened expression of transcription factor FOXM1 and its target genes protected cells against ...
Hendrika A. Segeren, Kathryn A. Wierenga, Frank M. Riemers, Elsbeth A. van Liere, Bart Westendorp   +4 more
wiley   +1 more source

Harnessing RNA therapeutics: novel approaches and emerging strategies for cardiovascular disease management. [PDF]

Front Cardiovasc Med
Dui W, Xiaobin Z, Haifeng Z, Lijuan D, Wenhui H, Zhengfeng Z, Jinling S.   +6 more
europepmc   +1 more source

Materia Medica, Pharmacy, and Therapeutics [PDF]

A.m. Sam'l O.l. Potter
openalex   +1 more source

Targeting PRAME directly or via EZH2 inhibition overcomes retinoid resistance and represents a novel therapy for keratinocyte carcinoma

Molecular Oncology, EarlyView.
The study evaluated the function and therapeutic implications of PRAME in basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). The findings demonstrate that PRAME impairs keratinocyte differentiation pathways. Furthermore, PRAME impairs anticancer response to retinoid compounds in BCC and SCC cells.
Brandon Ramchatesingh, Amelia Martinez Villarreal, Philippe Lefrançois, Jennifer Gantchev, Sriraam Sivachandran, Samy Abou Setah, Ivan V. Litvinov   +6 more
wiley   +1 more source

Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary. [PDF]

Future Oncol
de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Yoneshima Y, Kim SW, Linardou H, Novello S, van der Wekken AJ, Chen Y, Peters S, Felip E, Solomon BJ, Ramalingam SS, Dooms C, Lindsay CR, Ferreira CG, Blais N, Obiozor CC, Wang Y, Mehta B, Varrieur T, Ngarmchamnanrith G, Stollenwerk B, Waterhouse D, Paz-Ares L, CodeBreaK 200 Investigators.   +32 more
europepmc   +1 more source

A text-book of materia medica and therapeutics : characteristic, analytical, and comparative / by A.C. Cowperthwaite.

, 1891
A. C. Cowperthwaite
openalex   +2 more sources

The growth of siRNA-based therapeutics: updated clinical studies.

Biochemical Pharmacology, 2021
M. M. Zhang, R. Bahal, T. Rasmussen, J. Manautou, Xiao-bo Zhong   +4 more
semanticscholar   +1 more source

CircCCNB1 inhibits vasculogenic mimicry by sequestering NF90 to promote miR‐15b‐5p and miR‐7‐1‐3p processing in nasopharyngeal carcinoma

Molecular Oncology, EarlyView.
CircCCNB1 expression is down‐regulated in nasopharyngeal carcinoma (NPC); thus, less NF90 protein is bound to circCCNB1 and more binds to pri‐miRNAs, blocking their (pri‐miRNAs) binding to DGCR8 and inhibiting the processing and generation of miR‐15b‐5p/miR‐7‐1‐3p. Furthermore, decreased miR‐15b‐5p/miR‐7‐1‐3p promotes the expression of the target genes
Chunmei Fan, Fenghua Tan, Jie Wu, Zhaoyang Zeng, Wenjia Guo, He Huang, Wei Xiong   +6 more
wiley   +1 more source